Enhanced Antitumor Effects by the Coculture of Allotumor RNA-Pulsed Dendritic Cells with Autologous Cytokine-Induced Killer Cells on Hormone-Refractory Prostate Cancer

REFERENCES

• Jemal A., Murray T., Ward E., Samuels A., Tiwari R. C., Ghafoor A., Feuer E. J., Thun M. J. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• Tannock I. F., de Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Theodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–1512
   PubMed Web of Science ®Google Scholar
• Petrylak D. P., Tangen C. M., Hussain M. H., Lara P. N., Jones J. A., Taplin M. E., Burch P. A., Berry D., Moinpour C., Kohli M., Benson M. C., Small E. J., Raghavan D., Crawford E. D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513–1520
   PubMed Web of Science ®Google Scholar
• McNeel D. G., Malkovsky M. Immune-based therapies for prostate cancer. Immunol. Lett. 2005; 96: 3–9
   PubMed Web of Science ®Google Scholar
• Ragde H., Cavanagh W. A., Tjoa B. A. Dendritic cell based vaccines: Progress in immunotherapy studies for prostate cancer. J. Urol. 2004; 172: 2532–2538
   PubMedGoogle Scholar
• Fernandez N. C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., Perricaudet M., Tursz T., Maraskovsky E., Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 1999; 5: 405–411
   PubMed Web of Science ®Google Scholar
• Kadowaki N., Antonenko S., Ho S., Rissoan M. C., Soumelis V., Porcelli S. A., Lanier L. L., Liu Y. J. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 2001; 193: 1221–1226
   PubMed Web of Science ®Google Scholar
• Almand B., Resser J. R., Lindman B., Nadaf S., Clark J. I., Kwon E. D., Carbone D. P., Gabrilovich D. I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000; 6: 1755–1766
   PubMed Web of Science ®Google Scholar
• Fuessel S., Meye A., Schmitz M., Zastrow S., Clemens L., Richter K., Lobel B., Hakenberg O. W., Hoelig K., Rieber E. P., Wirth M. P. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial. Prostate. 2006; 66: 811–821
   PubMed Web of Science ®Google Scholar
• Nair S. K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J. S., Vieweg J., Gliboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 2000; 6(8)1011–1017
   PubMedGoogle Scholar
• Gilboa E., Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 2004; 199: 251–263
   PubMed Web of Science ®Google Scholar
• Grunebach F., Muller M. R., Nencioni A., Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther. 2003; 10: 367–374
   PubMed Web of Science ®Google Scholar
• Heiser A., Maurice M. A., Yancey D. R., Coleman D. M., Dahm P., Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001; 61: 3388–3393
   PubMed Web of Science ®Google Scholar
• Mu L. J., Gaudernack G., Saeboe-Larssen S., Hammerstad H., Tierens A., Kvalheim G. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand. J. Immunol. 2003; 58(5)578–586
   PubMed Web of Science ®Google Scholar
• Heiser A., Maurice M. A., Yancey D. R., Wu N. Z., Dahm P., Pruitt S. K., Boczkowski D., Nair S. K., Ballo M. S., Gilboa E., Vieweg J. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 2001; 166: 2953–2960
   PubMed Web of Science ®Google Scholar
• Mu L. J., Kyte J. A., Kvalheim G., Aamdal S., Dueland S., Hauser M., Hammerstad H., Waehre H., Raabe N., Gaudernack G. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br. J. Cancer. 2005; 93(7)749–756
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf I. G., Negrin R. S., Kiem H. P., Blume K. G., Weissman I. L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med. 1991; 174: 139–149
   PubMed Web of Science ®Google Scholar
• Lu P. H., Negrin R. S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 1994; 153: 1687–1696
   PubMed Web of Science ®Google Scholar
• Märten A., Ziske C., Schöttker B., Renoth S., Weineck S., Buttgereit P., Schakowski F., von Rücker A., Sauerbruch T., Schmidt-Wolf G. H. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J. Immunother. 2001; 24(6)502–510
   PubMed Web of Science ®Google Scholar
• Zhang S., Wang Q., Li W. F., Wang H. Y., Zhang H. J. Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates. Leuk. Res. 2004; 28(10)1085–1088
   PubMed Web of Science ®Google Scholar
• Marten A., Renoth S., von Lilienfeld-Toal M., Buttgereit P., Schakowski F., Glasmacher A., Sauerbruch T., Schmidt-Wolf I. G. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 2001; 86(10)1029–1037
   PubMedGoogle Scholar
• Wongkajornsilp A., Sangsuriyong S., Hongeng S., Waikakul S., Asavamong- kolkul A., Huabprasert S. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J. Orthop. Res. 2005; 23(6)1460–1466
   PubMed Web of Science ®Google Scholar
• Gonzalez-Carmona M. A., Marten A., Hoffmann P., Schneider C., Sievers E., Schmidt-Wolf I. G., Sauerbruch T., Caselmann W. H. Patient-derived dendritic cells transduced with an α -fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int. 2006; 26(3)369–379
   PubMed Web of Science ®Google Scholar
• Nair S. K., Boczkowski D., Morse M., Cumming R. I., Lyerly H. K., Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 1998; 16(4)364–369
   PubMed Web of Science ®Google Scholar
• Shaffer D. R., Scher H. I. Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol. 2003; 4: 407–414
   PubMed Web of Science ®Google Scholar
• Aalamian M., Pirtskhalaishvili G., Nunez A., Esche C., Shurin G. V., Huland E., Huland H., Shurin M. R. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 2001; 46(1)68–75
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y., Allmen E. U., von Moos R., Classon B. J., Scandella E., Schmid H. P., Ludewig B., Groettrup M., Gillessen S. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate 2005; 64(4)323–331
   PubMed Web of Science ®Google Scholar
• Verneris M. R., Karami M., Baker J., Jayaswal A., Negrin R. S. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004; 103: 3065–3072
   PubMed Web of Science ®Google Scholar
• Knutson K. L., Disis M. L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005; 54(8)721–728
   PubMed Web of Science ®Google Scholar
• Kornacker M., Moldenhauer G., Herbst M., Weilguni E., Tita-Nwa F., Harter C., Hensel M., Ho A. D. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int. J. Cancer. 2006; 119(6)1377–1382
   PubMed Web of Science ®Google Scholar
• Terabe M., Berzofsky J. A. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 2004; 16: 157–162, Review
   PubMed Web of Science ®Google Scholar